EPIRUS Biopharmaceuticals Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. EPIRUS Biopharmaceuticals prevailing Real Value cannot be determined due to lack of data. The current price of EPIRUS Biopharmaceuticals is $0.0. Our model computes the value of EPIRUS Biopharmaceuticals from examining the firm fundamentals such as shares outstanding of 26.18 M, and Operating Margin of (37.45) % as well as evaluating its technical indicators and probability of bankruptcy.
EPIRUS Biopharmaceutica Total Value Analysis
EPIRUS Biopharmaceuticals is currently projected to have takeover price of (6 M) with market capitalization of 157, debt of 14.85 M, and cash on hands of 20.86 M. The negative valuation of EPIRUS Biopharmaceutica may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the EPIRUS Biopharmaceutica fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(6 M) | 157 | 14.85 M | 20.86 M |
EPIRUS Biopharmaceutica Investor Information
The company has price-to-book (P/B) ratio of 0.0. Some equities with similar Price to Book (P/B) outperform the market in the long run. EPIRUS Biopharmaceuticals recorded a loss per share of 2.53. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 16th of July 2014. Based on the key measurements obtained from EPIRUS Biopharmaceutica's financial statements, EPIRUS Biopharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.EPIRUS Biopharmaceutica Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. EPIRUS Biopharmaceutica has an asset utilization ratio of 0.97 percent. This connotes that the Company is making $0.009701 for each dollar of assets. An increasing asset utilization means that EPIRUS Biopharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.EPIRUS Biopharmaceutica Profitability Analysis
The company reported the revenue of 701 K. Net Loss for the year was (52.19 M) with profit before overhead, payroll, taxes, and interest of 576 K.EPIRUS Biopharmaceutica Growth Indicators
Investing in growth stocks can be very risky. If the company such as EPIRUS Biopharmaceutica does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Retained Earnings | -138.8 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in EPIRUS Pink Sheet
If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |